Expanded [CCTG]n repetitions are not associated with abnormal methylation at the CNBP locus in myotonic dystrophy type 2 (DM2) patients

被引:10
|
作者
Santoro, Massimo [1 ]
Fontana, Luana [2 ]
Maiorca, Francesca [2 ]
Centofanti, Federica [2 ]
Massa, Roberto [3 ]
Silvestri, Gabriella [4 ]
Novelli, Giuseppe [2 ,5 ]
Botta, Annalisa [2 ]
机构
[1] Fdn Don C Gnocchi, Milan, Italy
[2] Univ Roma Tor Vergata, Med Genet Sect, Dept Biomed & Prevent, Rome, Italy
[3] Univ Roma Tor Vergata, Dept Syst Med Neurol, Rome, Italy
[4] Policlin Gemelli Fdn, Inst Neurol, Rome, Italy
[5] Neuromed IRCSS Pozzilli, Pozzilli, Italy
来源
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE | 2018年 / 1864卷 / 03期
关键词
Myotonic dystrophy type 2; Methylation; Bisulfite pyrosequencing; CNBP expression; CHLORIDE CHANNEL; CLCN1; MUTATIONS; MESSENGER-RNA; NUCLEAR FOCI; ZNF9; MUSCLE; EXPANSION; REPEATS; TRANSLATION; EXPRESSION;
D O I
10.1016/j.bbadis.2017.12.037
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Myotonic Dystrophy type 2 (DM2) is a multisystemic disorder associated with an expanded [CCTG]n repeat in intron 1 of the CNBP gene. Epigenetic modifications have been reported in many repeat expansion disorders, including myotonic dystrophy type 1 (DM1), either as a mechanism to explain somatic repeat instability or transcriptional alterations in disease genes. The purpose of our work was to determine the effect of DM2 mutation on the methylation status of CpG islands localized in the 5' promoter region and in the 3' end of the [CCTG]n expansion of the CNBP gene. By bisulfite pyrosequencing, we characterized the methylation profile of two different CpG islands within these regions, either in whole blood and skeletal muscle tissues of DM2 patients (n = 72 and n = 7, respectively) and controls (n = 50 and n = 7, respectively). Moreover, we compared the relative mRNA transcript levels of CNBP gene in leukocytes and in skeletal muscle tissues from controls and DM2 patients. We found that CpG sites located in the promoter region showed hypomethylation, whereas CpG sites at 3' end of the CCTG array are hypermethylated. Statistical analyses did not demonstrate any significant differences in the methylation profile between DM2 patients and controls in both tissues analyzed. According to the methylation analysis, CNBP gene expression levels are not significantly altered in DM2 patients. These results show that [CCTG]n repeat expansion, differently from the DM1 mutation, does not influence the methylation status of the CNBP gene and suggest that other molecular mechanisms are involved in the pathogenesis of DM2.
引用
收藏
页码:917 / 924
页数:8
相关论文
共 41 条
  • [1] Uninterrupted CCTG tracts in the myotonic dystrophy type 2 associated locus
    Radvanszky, Jan
    Surovy, Milan
    Polak, Emil
    Kadasi, Ludevit
    NEUROMUSCULAR DISORDERS, 2013, 23 (07) : 591 - 598
  • [2] Effect of the [CCTG]n repeat expansion on ZNF9 expression in myotonic dystrophy type II (DM2)
    Botta, A
    Caldarola, S
    Vallo, L
    Bonifazi, E
    Fruci, D
    Gullotta, F
    Massa, R
    Novelli, G
    Loreni, F
    BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE, 2006, 1762 (03): : 329 - 334
  • [3] The role of CNBP in brain atrophy and its targeting in myotonic dystrophy type 2
    Jennings, Katherine
    Lindquist, Diana
    Poonia, Ankita
    Schoser, Benedikt
    Schneider-Gold, Christiane
    Timchenko, Nikolai A.
    Timchenko, Lubov
    HUMAN MOLECULAR GENETICS, 2025, 34 (06) : 512 - 522
  • [4] The myotonic dystrophy type 2 (DM2) gene product zinc finger protein 9 (ZNF9) is associated with sarcomeres and normally localized in DM2 patients' muscles
    Massa, R.
    Panico, M. B.
    Caldarola, S.
    Fusco, F. R.
    Sabatelli, P.
    Terracciano, C.
    Botta, A.
    Novelli, G.
    Bernardi, G.
    Loreni, F.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2010, 36 (04) : 275 - 284
  • [5] (CCUG)n RNA toxicity in a Drosophila model of myotonic dystrophy type 2 (DM2) activates apoptosis
    Yenigun, Vildan Betul
    Sirito, Mario
    Amcheslavky, Alla
    Czernuszewicz, Tomek
    Colonques-Bellmunt, Jordi
    Garcia-Alcover, Irma
    Wojciechowska, Marzena
    Bolduc, Clare
    Chen, Zhihong
    Lopez Castel, Arturo
    Krahe, Ralf
    Bergmann, Andreas
    DISEASE MODELS & MECHANISMS, 2017, 10 (08) : 993 - 1003
  • [6] Alternative splicing alterations of Ca2+handling genes are associated with Ca2+signal dysregulation in myotonic dystrophy type 1 ( DM1) and type 2 ( DM2) myotubes
    Santoro, M.
    Piacentini, R.
    Masciullo, M.
    Bianchi, M. L. E.
    Modoni, A.
    Podda, M. V.
    Ricci, E.
    Silvestri, G.
    Grassi, C.
    NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY, 2014, 40 (04) : 464 - 476
  • [7] Co-segregation of DM2 with a recessive CLCN1 mutation in juvenile onset of myotonic dystrophy type 2
    Cardani, Rosanna
    Giagnacovo, Marzia
    Botta, Annalisa
    Rinaldi, Fabrizio
    Morgante, Alessandra
    Udd, Bjarne
    Raheem, Olayinka
    Penttila, Sini
    Suominen, Tiina
    Renna, Laura V.
    Sansone, Valeria
    Bugiardini, Enrico
    Novelli, Giuseppe
    Meola, Giovanni
    JOURNAL OF NEUROLOGY, 2012, 259 (10) : 2090 - 2099
  • [8] Dutch myotonic dystrophy type 2 patients and a North-African DM2 family carry the common European founder haplotype
    Coenen, Marieke J. H.
    Tieleman, Alide A.
    Schijvenaars, Mascha M. V. A. P.
    Leferink, Maike
    Ranum, Laura P. W.
    Scheffer, Hans
    van Engelen, Baziel G. M.
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2011, 19 (05) : 567 - 570
  • [9] Mutant (CCTG)n Expansion Causes Abnormal Expression of Zinc Finger Protein 9 (ZNF9) in Myotonic Dystrophy Type 2
    Raheem, Olayinka
    Olufemi, Shodimu Emmanuel
    Bachinski, Linda L.
    Vihola, Anna
    Sirito, Mario
    Hampf, Jeanette Holmlund
    Haapasalo, Hannu
    Li, Yi Ping
    Udd, Bjarne
    Krahe, Ralf
    AMERICAN JOURNAL OF PATHOLOGY, 2010, 177 (06) : 3025 - 3036
  • [10] Current Treatment Options for Patients with Myotonic Dystrophy Type 2
    Montagnese, Federica
    CURRENT TREATMENT OPTIONS IN NEUROLOGY, 2021, 23 (09)